EFFICACY OF 17α-Hydroxyprogesterone CAPROATE IN THE PREVENTION OF PREMATURE LABOR

Progesterone and preterm birth prevention: translating clinical trials data into clinical practice

“…(36) In 463 The estimated number of prevented PTBs < 37 weeks in the US by this policy is about 9,870 annually. (37) While the best evidence for efficacy is for 17P to be started before 21 weeks, beneficial effects have been reported when 17P is started by ≤27 weeks (38,39) 17P should not be stopped early (eg <32 weeks), as this is associated with increased incidence of PTB.…”

Comparative Study to Assess the Efficacy Between Intramuscular and Vaginal Micronized Progesterone to Prevent Threatened Premature Labour

“…18 So different trials have been done to show the efficacy and safety of progesterone in prevention of recurrent preterm birth since 1960. [19][20][21][22][23][24][25][26][27][28][29][30] Progesterone can be administered oral capsule, vaginal gel or suppository, or intramuscularly. Oral administration has better patient compliance but there is variability in the plasma concentrations of the drug due to personal variation in gastric filling and enterohepatic circulation, also this route might be associated with side effects such as nausea, headache, sleepiness, etc.…”

Progestins and Preterm Birth

“…Women are considered to be at high risk for several reasons, including past history of spontaneous PTB or miscarriages, multiple gestation, short cervical length (CL), cerclage in place and uterine anomalies. Earlier small trials using 17OHP-C showed mixed results; 4 trials reported benefit (LeVine, 1964;Papiernik, 1970;Johnson et al, 1975;Yemini et al, 1985), whereas 2 trials (Hartikainen-Sorri et al, 1980;Hauth et al, 1983) reported no benefit in reducing the risk of PTB. A metaanalysis over two decade ago (Kierse, 1990) showed that progesterone was beneficial in reducing PTL: odds ratio 0.43 (95% CI, 0.20-0.89); PTB: odds ratio 0.50 (95% CI, 0.30-0.85) and LBW (<2500g): odds ratio 0.50 (95% CI, 0.27-0.80).…”